Comparison of safety and outcomes related to remdesivir treatment among dialysis patients hospitalized with COVID-19.

Zaki, Kirollos E; Huang, Cheng-Wei; Zhou, Hui; Chung, Joanie; Selevan, David C; Rutkowski, Mark P; Sim, John J

Zaki, Kirollos E; Huang, Cheng-Wei; Zhou, Hui; Chung, Joanie; Selevan, David C; Rutkowski, Mark P; Sim, John J.

Afiliação

Zaki KE; Division of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
Huang CW; Department of Hospital Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
Zhou H; Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
Chung J; Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
Selevan DC; Department of Research and Evaluation Kaiser Permanente Southern California, Pasadena, CA, USA.
Rutkowski MP; Department of Research and Evaluation Kaiser Permanente Southern California, Pasadena, CA, USA.
Sim JJ; Regional Quality and Clinical Analysis, Southern California Permanente Medical Group Kaiser Permanente Southern California, Pasadena, CA, USA.

Clin Kidney J ; 15(11): 2056-2062, 2022 Nov.

Article em En | MEDLINE | ID: mdl-36320364

Palavras-chave

COVID-19; Remdesivir; end-stage kidney disease; outcomes; safety

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Clin Kidney J Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google